Sign In
Buy NEO
$15.29
-0.590 (-3.72%)
At Close: Jul 31, 2026
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
06:00am, Wednesday, 17'th Jun 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
Employers Tighten Focus on AI and Human Skills as Global Tech Hiring Moderates
12:00pm, Tuesday, 16'th Jun 2026
Employers Tighten Focus on AI and Human Skills as Global Tech Hiring Moderates PR Newswire MILWAUKEE, June 16, 2
Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 6
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
05:24pm, Monday, 15'th Jun 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes.
NeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100
08:54pm, Thursday, 28'th May 2026
On May 28, 2026, NeoGenomics Inc (NEO) shares rose 6.5% today, closing at $10.19. This movement comes amid a 52-week trading range between $4.72 and $13.74, ref
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
04:20pm, Wednesday, 20'th May 2026
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement
Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project
04:15pm, Wednesday, 20'th May 2026
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo reta
NeoGenomics to Participate in Upcoming Investor Conferences
10:00am, Friday, 15'th May 2026
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participat
NeoGenomics to Participate in Upcoming Investor Conferences
09:05am, Friday, 15'th May 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in t
Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript
01:00pm, Tuesday, 12'th May 2026
Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
07:00am, Tuesday, 12'th May 2026
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
09:00am, Tuesday, 05'th May 2026
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
03:51am, Wednesday, 29'th Apr 2026
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
NeoGenomics Reports First Quarter 2026 Results
04:05pm, Tuesday, 28'th Apr 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
07:05am, Thursday, 23'rd Apr 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' oncology testing portfolio is now available through Epic Aura.
